Annual general meeting

uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

Safety, Efficiency, Disease, BLA, GRIK2, ESGCT, Spinal cord, Cell, Marketing, Hippocampus, IPSC, Clinical trial, COVID-19, Temporal lobe epilepsy, Gene, Program, Acquisition, D, GLOBE, Locomotion, Liver, Spinocerebellar ataxia, Phase, Research, Neuron, SVB Leerink, Type III, Food, Mirna, Data monitoring committee, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, Annual report, Risk, Company, Hercules, Epilepsy, DSMB, Industry, CSL Behring, TLE, CSL, Sale, Heart, ALS, AAV, C9orf72, Fabry disease, Annual general meeting, Haemophilia, Technology, Huntington's disease, Patient, NASDAQ, FDA, Conference, Kidney, FIX, European Society of Gene and Cell Therapy, Forward-looking statement, Development, Animal, Pharmaceutical industry, Medical device, Vaccine, Cryptocurrency, Reinsurance
Monday, October 25, 2021 - 12:05pm

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Oct. 25, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2021 and highlighted recent progress across its business.

Key Points: 
  • and AMSTERDAM, The Netherlands, Oct. 25, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2021 and highlighted recent progress across its business.
  • Along with our global partner, CSL Behring, the Company expects to announce top-line data from the HOPE-B trial in the late fourth quarter of 2021.
  • As part of these efforts, the Company anticipates completing the validation of its commercial manufacturing process before year-end 2021.
  • In July 2021, the Company closed the acquisition of Corlieve Therapeutics, a pre-clinical gene therapy company based in France.

Mevion Selected to Equip Compact Proton Therapy Center in Kansas City

Hospitals, Health, Medical Devices, Proton, Science, Secondary malignant neoplasm, Annual general meeting, Research, Technology, Industry, Radiation therapy, LinkedIn, Adoption, Patient, McCormick Place, MLC, Risk, Lead, FLASH, Proton therapy, CEO, American Society for Radiation Oncology, Multimedia, Motion, ASTRO, Varian Medical Systems, Sale, Society, Medical imaging
Monday, October 25, 2021 - 12:00pm

The size and cost of larger proton technologies has been a major impediment to the adoption of proton therapy.

Key Points: 
  • The size and cost of larger proton technologies has been a major impediment to the adoption of proton therapy.
  • Today, new proton therapy centers in the US are almost exclusively compact single-room systems and Mevion is the preferred compact provider in the US.
  • Kansas City Urology Care is the premier center for urology care in Kansas City that assures cutting-edge treatment solutions for all forms of urological conditions.
  • Mevions flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the worlds smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems.

CytoDyn Announces Treatment of First Patient in Pivotal Phase 3 Trial for Critically Ill COVID-19 Patients in Brazil

Fatty liver disease, Vaccine, Partnership, THE, BLA, U.S. Securities and Exchange Commission, SARS, PASC, Triple-negative breast cancer, Government budget balance, Clinical trial, Biomarker, COVID-19, Inflammation, Sleep, HIV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HIV/AIDS, BLUE, Human, Cirrhosis, Security (finance), HAART, Food, Company, Biologics license application, ME/CFS, Degenerative disease, Social conditions in Honduras, Viral load, Fibrosis, Immunoglobulin G, Compliance, Common, Fast Track, Myalgia, Calendar, Suite, SEC, Refusal, Optimism, CD16, Fatigue, XV, Risk, Annual general meeting, Main Street, NAFLD, CCR5, Patient, FDA, 100,000, Professional, Forward-looking statement, Standard of care, Cell, Form 10-K, NASH, Pharmaceutical industry
Monday, October 25, 2021 - 11:00am

VANCOUVER, Washington, Oct. 25, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the treatment of the first patient in its pivotal Phase 3 trial (CD16) in Brazil for critically ill COVID-19 patients. An interim analysis will be conducted 28 days following the enrollment of 127 patients. On September 9, 2021, the Company announced the treatment of the first patient in its other pivotal Phase 3 trial in Brazil (CD17). An interim analysis for this trial will be conducted 28 days after 245 patients have been enrolled.

Key Points: 
  • The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC).
  • CytoDyn is also conducting a Phase 2 clinical trial for NASH to evaluate the effect of leronlimab on liver steatosis and fibrosis.
  • CytoDyn successfully completed a Phase 3 pivotal trial using leronlimab combined with standard antiretroviral therapies in HIV-infected patients who were heavily treatment-experienced individuals with limited treatment options.
  • CytoDyn also completed a Phase 2b/3 investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients.

Biotage appoints Nomination Committee

Science, Food safety, Nomination, Annual, Group, Capital, Committee, Nasdaq Stockholm, Human, Organization, Person, CET, Drug discovery, BIOT, Board, Letter, Annual general meeting, Director, Water, Management
Monday, October 25, 2021 - 10:50am

The Nomination Committee shall, before the Annual General Meeting 2022, prepare proposal for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual General Meeting, election of Auditors, the determination of fees and matters pertaining thereto.

Key Points: 
  • The Nomination Committee shall, before the Annual General Meeting 2022, prepare proposal for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual General Meeting, election of Auditors, the determination of fees and matters pertaining thereto.
  • The members of the Nominations Committee are:
    Shareholders wishing to submit a proposal to the Nomination Committee may do so by sending e-mail to the Chairman of the Board of Directors of Biotage AB at: info@biotage.com .
  • Proposals should, in order to be timely assessed by the Nomination Committee, be submitted no later than seven weeks in advance of the meeting.
  • The Annual General Meeting 2022 in Biotage will be held on Thursday, April 28, 2022 at 4:00pm CET in Uppsala.

Custodian Ventures Addresses My Size, Inc.’s Latest Attempt to Disenfranchise Stockholders and Undermine Corporate Democracy

Annual general meeting, NASDAQ, Stock dilution, Interpol, Company, Board, Annual Meetings of the International Monetary Fund and the World Bank Group, GLOBE, Ownership, Holding company, Financial adviser
Friday, October 22, 2021 - 2:16pm

David Lazar, Chief Executive Officer of Custodian Ventures, stated:

Key Points: 
  • David Lazar, Chief Executive Officer of Custodian Ventures, stated:
    The lawsuit filed by MYSZ is baseless and we intend on vigorously defending ourselves.
  • This action appears to be a blatant entrenchment maneuver intended to disenfranchise Custodian Ventures and insulate Ronen Luzon and his boardroom allies, who have demonstrated a flagrant disregard for stockholders and their rights for years.
  • We contend that the incumbent Board has irreparably impugned its credibility by weaponizing litigation in an attempt to silence a sizable stockholder and undermine corporate democracy.
  • Custodian Ventures LLC is an investment fund specializing in reverse merger and other event driven opportunities.

Kimball Electronics, Inc. Announces Date for Reporting First Quarter Fiscal 2022 Financial Results

Hardware, Manufacturing, Other Manufacturing, Other Technology, Technology, Annual general meeting, KE, Electronics, Review, COVID-19, Solution, Nasdaq, Temperature, Animal
Friday, October 22, 2021 - 1:35pm

Kimball Electronics, Inc. (Nasdaq: KE) today announced that it will report first quarter fiscal 2022 financial results on Wednesday, November 3, 2021 after the closing of the market.

Key Points: 
  • Kimball Electronics, Inc. (Nasdaq: KE) today announced that it will report first quarter fiscal 2022 financial results on Wednesday, November 3, 2021 after the closing of the market.
  • The telephone number to access the conference call is 877-248-9893 in the United States, or 873-415-0287 for other locations.
  • The meeting is scheduled to take place at the Kimball Electronics, Inc. Headquarters at 1205 Kimball Blvd.
  • Kimball Electronics is a multifaceted manufacturing solutions provider of electronics and diversified contract manufacturing services to customers around the world.

Sun Nuclear Presents Independent, Integrated Quality Management Solutions at 2021 ASTRO Annual Meeting

Yellow Sun (nuclear weapon), Quality, Annual general meeting, GA, Efficiency, Technology, Diagnosis, Cancer, Emory University, Software as a service, Patient safety, TAQA, Adoption, Winship Cancer Institute, MLC, Comparison, Society, Quality management, Breath gas analysis, SRS, Learning, Multimedia, Solution, Acquisition, Radiation, ASTRO, QA, Prevalence, Radiation therapy, Medical imaging, Online shopping
Friday, October 22, 2021 - 1:00pm

MELBOURNE, Fla., Oct. 22, 2021 /PRNewswire/ --Sun Nuclear, part of Mirion Technologies, announced today that during the 2021 ASTRO Annual Meeting , October 24-26 in Chicago, Illinois, Sun Nuclear will feature its leading Quality Management solutions for radiation therapy in Booth #1029, with daily demonstrations and in-booth talks from clinical users.

Key Points: 
  • MELBOURNE, Fla., Oct. 22, 2021 /PRNewswire/ --Sun Nuclear, part of Mirion Technologies, announced today that during the 2021 ASTRO Annual Meeting , October 24-26 in Chicago, Illinois, Sun Nuclear will feature its leading Quality Management solutions for radiation therapy in Booth #1029, with daily demonstrations and in-booth talks from clinical users.
  • ASTRO attendees are invited to learn more about the independent, integrated QA solutions available for Radiation Therapy.
  • As demands continue to grow for Radiation Therapy departments, clinical and operational efficiency is essential for effective Quality Management.
  • Sun Nuclear is also a sponsor of the 2021 SROA (Society for Radiation Oncology Administrators) Annual Meeting , October 24-26.

Palatin Awarded "Top 10 Poster" Designation at the American Society of Retina Specialists (ASRS) 2021 Annual Meeting

PTN, Bremelanotide, Diabetic retinopathy, Annual general meeting, Research, Biotechnology, Inflammation, Technology, Poster, Retina, Securities Act of 1933, 5-HT receptor, ASRS, Drug development, Security (finance), U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, FDA, View, NYSE, Eye, Retinopathy, Melanocortin, Kidney, Senior, Marketing, CEO, Tissue, Multimedia, Metabolism, Drug Quality and Security Act, Doctor of Philosophy, Securities Exchange Act of 1934, Choroidal neovascularization, Society, Fine chemical, Pharmaceutical industry
Friday, October 22, 2021 - 12:30pm

"We are honored to have our poster recognized by ASRS as a Top 10 poster," said John Dodd, PhD, Senior Vice President of Preclinical Research at Palatin.

Key Points: 
  • "We are honored to have our poster recognized by ASRS as a Top 10 poster," said John Dodd, PhD, Senior Vice President of Preclinical Research at Palatin.
  • "It speaks to the interest and enthusiasm in the scientific community about the potential of the melanocortin mechanism to treat inflammatory conditions.
  • We are excited to share this retina and other inflammatory disease model data where we see melanocortin agonists work so well."
  • Palatin is not responsible for updating for events that occur after the date of this press release.

Plus Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

Safety, Nuclear medicine, Neurology, American Society for Radiation Oncology, Annual general meeting, Cancer, Compliance, Brain, Research, Pakistan Society of Neuro-Oncology, Radiation, PBC, University of Texas at Austin, Radiation therapy, Neoplasm, Monroe Dunaway Anderson, Patient, FDA, UT Health East Texas - North Campus, Associate professor, Completeness, Food, GMP, SNO, GBM, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Â, Senior, CMC, University, Investigational New Drug, Company, Clinical trial, LM, University of Texas Southwestern Medical Center, EST, Molecular imaging, PSTV, IND, University of Texas Health Science Center at San Antonio, Education, Nasdaq, ASTRO, Therapy, GLOBE, Toxic leukoencephalopathy, Incidence, Department, Specialization, Society, ClinicalTrials.gov, Pharmaceutical industry, Dietary supplement
Thursday, October 21, 2021 - 9:05pm

AUSTIN, Texas, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the Company), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the third quarter ended September 30, 2021, and provided an overview of recent business highlights.

Key Points: 
  • AUSTIN, Texas, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the Company), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the third quarter ended September 30, 2021, and provided an overview of recent business highlights.
  • The Company expects to initiate patient accrual in a Phase 1 dose escalation trial of 186RNL (ReSPECT-LM) in the fourth quarter of 2021.
  • Total operating expenses for the third quarter of 2021 were $3.5 million, compared to total operating expenses of $1.4 million for the same quarter in 2020.
  • The Company will hold a conference call and live audio webcast at 5:00 p.m. Eastern Time today to discuss its financial results and provide a general business update.

David Hall, Founder of Velodyne Lidar, Announces Intent to Nominate Highly-Qualified Director Candidates for Election at the Company’s 2022 Annual Meeting

Software, Technology, Hardware, Annual general meeting, Engineering, Research, Technology, Velodyne Lidar, WHEN, NO, UPON, Velodyne, Common stock, THE, Security (finance), Common, U.S. Securities and Exchange Commission, NASDAQ, SPAC, WEB, SEC, Face, Leadership, Software, Company, RSU, Board, CEO, Acquisition, G&A, Shareholder, Director, Holding company, Management, Animal, Auction
Thursday, October 21, 2021 - 3:00pm

In my view, the only way to turn around Velodyne Lidar is to rid the Board of its seemingly self-interested and underqualified members.

Key Points: 
  • In my view, the only way to turn around Velodyne Lidar is to rid the Board of its seemingly self-interested and underqualified members.
  • As the Companys largest stockholder, I will not allow Velodyne Lidar to continue to stagnate under current leadership, which is why I intend to nominate two highly-qualified director candidates for election to Velodyne Lidars Board at the Companys 2022 Annual Meeting of Stockholders to replace Messrs. Dee and Thomas.
  • Thankfully, stockholders will have an opportunity at the 2022 Annual Meeting to elect new directors with corporate governance and technology experience to Velodyne Lidars Board.
  • I look forward to continuing actively engaging with my fellow stockholders and Company leadership in the months leading up to Velodyne Lidars 2022 Annual Meeting.